Fecal microbiota transplantation (FMT) has emerged as a highly effective treatment for recurrent Clostridium difficile (C. difficile) infection, with very early experience suggesting that it may also play a role in treating other gastrointestinal (GI) and non-GI diseases. The topic is examined in the Review Article, "An overview of fecal microbiota transplantation: techniques, indications, and outcomes" in the August issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE). Also in this issue, the journal launches a new section called VideoGIE, which features high-quality videos of endoscopic procedures.
Fecal microbiota transplantation refers to the infusion of a suspension of fecal matter from a healthy individual into the GI tract of another person to cure a specific disease. FMT has received public attention recently with the publication of several studies showing that stool is a biologically active, complex mixture of living organisms with great therapeutic potential for Clostridium difficile infection and perhaps other GI and non-GI disorders. C. difficile is a bacterium recognized as the major causative agent of colitis (inflammation of the colon) and diarrhea that may occur following antibiotic intake. The disruption of the normal balance of colonic microbiota as a consequence of antibiotic use or other stresses can result in C. difficile infection. It is now estimated that 500,000 to 3 million cases of C. difficile occur annually in U.S. hospitals and long-term care facilities.
According to authors Lawrence J. Brandt, MD and Olga C. Aroniadis, MD, Montefiore Medical Center, Bronx, New York, current first-line treatment for C. difficile includes cessation of the culprit antibiotic, if possible, and treatment with metronidazole, vancomycin, or fidaxomicin, depending on disease severity. Most patients with C. difficile initially respond to this treatment, but recurrence rates are 15 percent to 35 percent. Patients who have one recurrence have up to a 45 percent chance of a second recurrence, and after a second recurrence, up to 65 percent of patients will have a third. Recurrences are usually treated with additional courses of metronidazole, oral vancomycin, or prolonged oral vancomycin in various pulsed-tapered regimens, occasionally "chased" by other antibiotics such as rifaximin. The high recurrence rates of C. difficile prompted the need for alternative therapies, to which the authors believe FMT offers a rational and relatively simple approach.
The Review Article addresses FMT methodology, including donor and recipient screening, donor selection, how FMT is performed and safety. FMT is most commonly performed via colonoscopy; however, donor feces also have been administered via a nasogastric or nasoenteric tube, gastroduodenoscopy, and enema. All the studies have reported remarkable cure rates without serious adverse effects directly attributable to FMT. The article notes that current literature on FMT for C. difficile predominantly comprises single-center case series and case reports, but also a meta-analysis, two systematic reviews, and one recently published randomized, controlled trial. In all, 92 percent of patients were cured of their recurrent C. difficile, with a range of 81 percent to 100 percent. In the only long-term follow-up study of FMT to date that included 5-medical centers and 77 patients who had FMT, the patients experienced a 91 percent primary cure rate and an astounding 98 percent secondary cure rate, the latter defined as cure enabled by use of antibiotics to which the patient had not responded before the FMT or by a second FMT. Patients in this study had symptoms for an average of 11 months before FMT, and most (74 percent) reported resolution of diarrhea within three days. FMT also has been successfully used to treat a variety of other GI disorders including inflammatory bowel disease, irritable bowel syndrome, and constipation. There is a growing literature on an altered intestinal microbiome in these and other disorders.
Explore further: Fecal microbiota tx feasible for recurrent C. difficile in HIV
More information: www.giejournal.org/
Medical Xpress on facebook
Related Stories
Fecal microbiota transplants effective treatment for C. difficile, Inflammatory Bowel Disease
Oct 31, 2011
Growing evidence for the effectiveness of fecal microbiota transplants as a treatment for patients with recurrent bouts of Clostridium difficile (C.difficile) associated diarrhea is presented in three studies -- including ...
Fecal microbiota tx feasible for recurrent C. difficile in HIV
May 22, 2013
(HealthDay)—For HIV-infected individuals with recurrent Clostridium difficile infection, fecal microbiota therapy is feasible, according to a letter published in the May 21 issue of the Annals of Intern ...
A new treatment option for Clostridium difficile: Fecal transplantation
Mar 14, 2012
Fecal transplantation through colonoscopy is an effective treatment for recurrent Clostridium difficile infection (CDI), according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. ...
Fecal transplant feasible for recurrent <i>C. difficile</i> infection
Mar 03, 2012
(HealthDay) -- Recurrent Clostridium difficile (C. difficile) infection (CDI) can successfully be treated in the vast majority of patients through a fecal transplantation procedure via colonoscopy, according to ...
Groundbreaking clinical trial looks at fecal transplant as treatment for C. difficile
Aug 21, 2012
For patients with Clostridium difficile (C. difficile), a persistent and potentially deadly bacterial illness, severe diarrhea, abdominal pain, nausea and vomiting are an everyday event. This particularly virulent infection is ...
Recommended for you
Two alternative treatments may help relieve postoperative nausea
6 hours ago
Two simple, non-drug treatments—aromatherapy and intravenous administration of a simple sugar solution—may offer effective new approaches to relieving nausea and vomiting after surgery, report a pair of studies in the ...
Hand transplantation: A Swiss research success
9 hours ago
Hope for hand amputees: researchers at Inselspital and the University of Bern have successfully tested a new method for local immunosuppression.
Unemployment restricts access to kidney transplants, study finds
Aug 20, 2013
People in end-stage kidney failure in need of a kidney transplant are much less likely to be placed on a waiting list for a new kidney or to actually receive a new kidney once on the list if they are unemployed or work part ...
Hip protectors with a sporty look
Aug 15, 2013
Norwegian researchers have developed a hip protector in a sporty design. Its looks are intended to appeal to the older people of today – who are quite particular about what they will wear.
Conflicts of interest common among panel members of guidelines that expand disease definitions
Aug 13, 2013
An assessment of expert members of panels making decisions about definitions or diagnostic criteria for common conditions in the US, which were published in guidelines used by physicians and other healthcare professionals ...
Toxicologist says NAS panel 'misled the world' when adopting radiation exposure guidelines
Aug 13, 2013
In two recently published peer-reviewed articles, toxicologist Edward Calabrese of the University of Massachusetts Amherst describes how regulators came to adopt the linear no threshold (LNT) dose-response approach to ionizing ...
User comments
© Medical Xpress 2011-2013, Phys.org network
Fecal microbiota transplantation (FMT) has emerged as a highly effective treatment for recurrent Clostridium difficile (C. difficile) infection, with very early experience suggesting that it may also play a role in treating other gastrointestinal (GI) and non-GI diseases. The topic is examined in the Review Article, "An overview of fecal microbiota transplantation: techniques, indications, and outcomes" in the August issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE). Also in this issue, the journal launches a new section called VideoGIE, which features high-quality videos of endoscopic procedures.
Fecal microbiota transplantation refers to the infusion of a suspension of fecal matter from a healthy individual into the GI tract of another person to cure a specific disease. FMT has received public attention recently with the publication of several studies showing that stool is a biologically active, complex mixture of living organisms with great therapeutic potential for Clostridium difficile infection and perhaps other GI and non-GI disorders. C. difficile is a bacterium recognized as the major causative agent of colitis (inflammation of the colon) and diarrhea that may occur following antibiotic intake. The disruption of the normal balance of colonic microbiota as a consequence of antibiotic use or other stresses can result in C. difficile infection. It is now estimated that 500,000 to 3 million cases of C. difficile occur annually in U.S. hospitals and long-term care facilities.
According to authors Lawrence J. Brandt, MD and Olga C. Aroniadis, MD, Montefiore Medical Center, Bronx, New York, current first-line treatment for C. difficile includes cessation of the culprit antibiotic, if possible, and treatment with metronidazole, vancomycin, or fidaxomicin, depending on disease severity. Most patients with C. difficile initially respond to this treatment, but recurrence rates are 15 percent to 35 percent. Patients who have one recurrence have up to a 45 percent chance of a second recurrence, and after a second recurrence, up to 65 percent of patients will have a third. Recurrences are usually treated with additional courses of metronidazole, oral vancomycin, or prolonged oral vancomycin in various pulsed-tapered regimens, occasionally "chased" by other antibiotics such as rifaximin. The high recurrence rates of C. difficile prompted the need for alternative therapies, to which the authors believe FMT offers a rational and relatively simple approach.
The Review Article addresses FMT methodology, including donor and recipient screening, donor selection, how FMT is performed and safety. FMT is most commonly performed via colonoscopy; however, donor feces also have been administered via a nasogastric or nasoenteric tube, gastroduodenoscopy, and enema. All the studies have reported remarkable cure rates without serious adverse effects directly attributable to FMT. The article notes that current literature on FMT for C. difficile predominantly comprises single-center case series and case reports, but also a meta-analysis, two systematic reviews, and one recently published randomized, controlled trial. In all, 92 percent of patients were cured of their recurrent C. difficile, with a range of 81 percent to 100 percent. In the only long-term follow-up study of FMT to date that included 5-medical centers and 77 patients who had FMT, the patients experienced a 91 percent primary cure rate and an astounding 98 percent secondary cure rate, the latter defined as cure enabled by use of antibiotics to which the patient had not responded before the FMT or by a second FMT. Patients in this study had symptoms for an average of 11 months before FMT, and most (74 percent) reported resolution of diarrhea within three days. FMT also has been successfully used to treat a variety of other GI disorders including inflammatory bowel disease, irritable bowel syndrome, and constipation. There is a growing literature on an altered intestinal microbiome in these and other disorders.
Explore further: Fecal microbiota tx feasible for recurrent C. difficile in HIV
More information: www.giejournal.org/
Medical Xpress on facebook
Related Stories
Fecal microbiota transplants effective treatment for C. difficile, Inflammatory Bowel Disease
Oct 31, 2011
Growing evidence for the effectiveness of fecal microbiota transplants as a treatment for patients with recurrent bouts of Clostridium difficile (C.difficile) associated diarrhea is presented in three studies -- including ...
Fecal microbiota tx feasible for recurrent C. difficile in HIV
May 22, 2013
(HealthDay)—For HIV-infected individuals with recurrent Clostridium difficile infection, fecal microbiota therapy is feasible, according to a letter published in the May 21 issue of the Annals of Intern ...
A new treatment option for Clostridium difficile: Fecal transplantation
Mar 14, 2012
Fecal transplantation through colonoscopy is an effective treatment for recurrent Clostridium difficile infection (CDI), according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. ...
Fecal transplant feasible for recurrent <i>C. difficile</i> infection
Mar 03, 2012
(HealthDay) -- Recurrent Clostridium difficile (C. difficile) infection (CDI) can successfully be treated in the vast majority of patients through a fecal transplantation procedure via colonoscopy, according to ...
Groundbreaking clinical trial looks at fecal transplant as treatment for C. difficile
Aug 21, 2012
For patients with Clostridium difficile (C. difficile), a persistent and potentially deadly bacterial illness, severe diarrhea, abdominal pain, nausea and vomiting are an everyday event. This particularly virulent infection is ...
Recommended for you
Two alternative treatments may help relieve postoperative nausea
6 hours ago
Two simple, non-drug treatments—aromatherapy and intravenous administration of a simple sugar solution—may offer effective new approaches to relieving nausea and vomiting after surgery, report a pair of studies in the ...
Hand transplantation: A Swiss research success
9 hours ago
Hope for hand amputees: researchers at Inselspital and the University of Bern have successfully tested a new method for local immunosuppression.
Unemployment restricts access to kidney transplants, study finds
Aug 20, 2013
People in end-stage kidney failure in need of a kidney transplant are much less likely to be placed on a waiting list for a new kidney or to actually receive a new kidney once on the list if they are unemployed or work part ...
Hip protectors with a sporty look
Aug 15, 2013
Norwegian researchers have developed a hip protector in a sporty design. Its looks are intended to appeal to the older people of today – who are quite particular about what they will wear.
Conflicts of interest common among panel members of guidelines that expand disease definitions
Aug 13, 2013
An assessment of expert members of panels making decisions about definitions or diagnostic criteria for common conditions in the US, which were published in guidelines used by physicians and other healthcare professionals ...
Toxicologist says NAS panel 'misled the world' when adopting radiation exposure guidelines
Aug 13, 2013
In two recently published peer-reviewed articles, toxicologist Edward Calabrese of the University of Massachusetts Amherst describes how regulators came to adopt the linear no threshold (LNT) dose-response approach to ionizing ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment